A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Duligotuzumab (Primary) ; Cetuximab; Fluorouracil; Folic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 17 Feb 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 23 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Planned End Date changed from 1 Jan 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.